Chimerix signs antiviral deal with Merck; FDA approves interactive insulin pump;

> Chimerix, which uses its lipid-antiviral conjugate technology to improve drug delivery, has signed a deal with Merck ($MRK), giving it access to the HIV antiviral CMX157. Article

> The FDA has approved Roche's ($RHHBY) Accu-Chek Combo interactive insulin pump system. Article

> A hyaluronic acid drug delivery system, delivering 5-fluorouracil over several weeks, could reduce scarring after glaucoma surgery. The study has been shortlisted for a Best Clinical Research Oral Presentation Award at the second SingHealth Duke-NUS Scientific Congress. Article

> NeuroDerm, a transdermal drug delivery developer, is raising $15 million. Article

> Opko Health has signed a research and license agreement for a topically active formulation of the anti-VEGF antibody, ranibizumab, to treat diabetic macular edema. Article

> Airway-targeted PLGA nanoparticles could deliver drugs in obstructive lung disease. Abstract

And Finally… An RNAi drug delivery company secures $1.6M for endosomal escape technology. Article

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.